Compare Medtronic PLC (MDT) vs ArcelorMittal SA (MT) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

ArcelorMittal (MT) trades at $65.81, down 0.96% on the day but remains near its 52-week high of $72.50. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent developments include a strategic AI collaboration with AWS and ongoing share buybacks, while analyst sentiment is mixed with 50% recommending Buy.

Outlook: MT presents value with attractive P/E (17.4) and P/B (0.91) ratios, supported by rising net margins. Risks include declining revenue trends, high capital expenditures, and exposure to steel market volatility. The stock's upside depends on execution of expansion projects and stable commodity pricing.